ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / ADRX / options
BRVE (46) TRAX (44) MLYS (34) ZBIO (40) ⌘ Pro Terminal →

ADARx Pharmaceuticals Inc. (ADRX) Options Positioning, Max Pain & Unusual Sweeps

$17.00 -4.76% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $16.82

ADARx Pharmaceuticals Inc. (ADRX) carries a Roarable Rating of D (Sell) with 51/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 51/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.3% avg 90D alpha vs SPY) →
ROARABLE D • SELL / AVOID Cap $1.91B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ADRX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ADRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, ADARx Pharmaceuticals Inc. (NASDAQ: ADRX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 51/100 at a spot price of $17.00 (-4.76% 1D, market cap $1.91B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, ADRX ranks #283 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ADRX compare to BRVE and TRAX in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ADRX carries a Roarable D (51/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, BRVE (Braveheart Bio Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $1.91B) and TRAX (First Tracks Biotherapeutics Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $1.90B). Among the 5-stock peer group, ADRX leads on earnings multiple (N/A) while MLYS leads on capital efficiency (-28.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ADRX?
▼

For ADARx Pharmaceuticals Inc. (ADRX), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #283 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $16.82 (-1.05%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 1.3% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 51/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.3% avg 90D alpha vs SPY • 49.7% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510051
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk C
Cash (12)Whales (5)SEC (13)Macro (12)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-3.2% Base Target
$24 Bull$16 Base$13 Bear
📬 FREE ADRX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ADRX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (51/100 Composite)
🔍 WHY ADRX SCORES 51/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (25% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (24% of score)

SEC XBRL Trailing 12 Months: 1.3% FCF Margin ($53.4M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning5/20 pts (-15 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
59
Grade C$17.97-1.9% Next Q
Q2 (-2Q)
56
Grade C$17.63+1% Next Q
Q3 (-1Q)
54
Grade C-$17.81-4.5% Next Q
Current
51
Grade D$17.00-1.3% Hist 90D α
Trajectory: C (59) → D (51)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ADRX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ADRX currently carries a cautious 51/100 (D) rating due to Whale & Options Positioning (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($18.12) and Max Pain ($17.85) forces dealer call-delta covering toward $24.37.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ADRX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ADRX Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 51%NO 49%Trade / Inspect Odds →
CALL VS. PUT WHALE SHARE
— (No Active Options Snapshot)
Put/Call Ratio: — (No Active Options Snapshot)
MAX-PAIN EXPIRATION MAGNET
— (No Active Options Snapshot)
No active options chain max-pain snapshot on file
HISTORICAL 20D VOLATILITY SWING
±12.5%
Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (ADRX)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for ADRX.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ADRX)

  • ✓Walkthrough of ADRX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
ADRX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -12.14%🛡️ HOLDING TREND SUPPORT
2026-11-02O $16.95H $17.03L $15.71C $17.00VOL 378.6K
RES: $19.21SUP: $16.58SMA50: $18.12
$23.74$21.56$19.38$17.21$15.04RES $19.21SUP $16.58$17.002026-09-252026-10-052026-10-142026-10-222026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ADRX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ADRX Butterfly Map → + Track ADRX →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ADRX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ADRX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ADRX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ADRX)

Health Care Rank #283 of 1016 ⚔️ BRVE vs ADRX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ADRX vs. BRVE, TRAX, MLYS, ZBIO)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, ADARx Pharmaceuticals Inc. (ADRX) ranks #283 by composite RQD confidence (51/100, grade D) and #272 by equity capitalization ($1.91B). Within this direct 5-issuer industry benchmark cohort, ADRX leads on earnings valuation at N/A trailing P/E, while MLYS leads on capital efficiency and profitability with -28.4% ROIC and — gross margin. ADRX currently leads its immediate peer cohort in composite quantitative strength at 51/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ADRX ACTIVE
ADARx Pharmaceuticals Inc.
D 51/100 — — — -4.76% $1.91B Benchmark Subject
BRVE
Braveheart Bio Inc.
D 46/100 — — — +1.51% $1.91B /brve-vs-adrx →
TRAX
First Tracks Biotherapeutics Inc.
D 44/100 — — -35.0% -0.32% $1.90B /trax-vs-adrx →
MLYS
Mineralys Therapeutics Inc.
E 34/100 — — -28.4% -14.41% $1.88B /mlys-vs-adrx →
ZBIO
Zenas BioPharma Inc.
D- 40/100 — — -35.0% -1.29% $1.87B /zbio-vs-adrx →

2. ADRX Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

ADARx Pharmaceuticals Inc. (ADRX) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $1.91B, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. ADRX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ADRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, ADARx Pharmaceuticals Inc. (NASDAQ: ADRX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 51/100 at a spot price of $17.00 (-4.76% 1D, market cap $1.91B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, ADRX ranks #283 in composite RQD confidence.

How does ADRX compare to BRVE and TRAX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ADRX carries a Roarable D (51/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, BRVE (Braveheart Bio Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $1.91B) and TRAX (First Tracks Biotherapeutics Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $1.90B). Among the 5-stock peer group, ADRX leads on earnings multiple (N/A) while MLYS leads on capital efficiency (-28.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ADRX?

For ADARx Pharmaceuticals Inc. (ADRX), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #283 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ADRX trading relative to its 50-day, 200-day, and 52-week technical levels?

ADRX last traded at $17.00 (-4.76% on volume of 542,284 shares), positioning the stock -6.18% below its 50-day simple moving average ($18.12) and -6.39% below its 200-day simple moving average ($18.16). Across its 52-week range of $15.71 to $23.21, ADRX sits at the 17.2% percentile with a 14-day RSI of 29.7 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($14.87 to $19.13).

ADRX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is ADRX's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for ADRX.

Direct Sub-Reports: ADRX RQD Cockpit ADRX 12M Forecast ADRX Earnings & Move ADRX Dividends & DRIP ADRX Insiders & 13F ADRX Whale Options ADRX Profit Sankey ADRX News & Why
ROARABLE RATING BRIEF • RQD 51/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

ADRX — ADARx Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T14:12:53Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, ADRX carries an RQD Score of 51 and a letter grade of D, labeled "Roarable Sell — Underperform / Distribution Warning." The five pillars are:

  • Fundamental Cash Engine: 12 / 20. The rating cites ROIC of 0% and FCF yield of 0%. For a prospective investor, the cash-generation case is currently unproven in the source data.
  • Whale 13F Flow: 5 / 20. Described as institutional accumulation and options positioning. This is the lowest pillar and suggests weak institutional support in the source data.
  • Insider Conviction: 9 / 20. Described as SEC Form 4 and Congressional PTR cluster flow. Insider signals are modest per this pillar.
  • Macro Regime Fit: 12 / 20. Beta of 1.0 and sector sensitivity are cited. The stock is rated as moving in line with the broader market rather than offering defensive or differentiated behavior.
  • Forensic Balance Sheet: 13 / 20. Altman Z of 2.5, Piotroski F of 6/9, and Debt/Equity of 0.5 are cited. This is the strongest pillar, indicating a balance sheet that is more stable than the cash-flow and flow pillars.

Investor implications: the upside case rests on the balance-sheet strength and on the catalyst flow below; the valuation tradeoff is that without reported earnings, cash flow, or P/E data, the rating cannot distinguish between a pre-profit growth profile and a stalled one. The rating's sell label reflects weak cash returns and institutional flow rather than balance-sheet distress.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links. Sector is Health Care and industry is Biotechnology: Pharmaceutical Preparations. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are not available in source data.

Open Questions

  • What are the reported revenue, operating income, and net income figures, given that the financials section contains no data?
  • What is the ADARx siRNA pipeline's clinical stage and timeline, and what does the source identify as its catalysts?
  • Why does the rating show ROIC and FCF yield of 0%, and what is the company's path to positive cash generation?
  • Which price is current: the market-data price of 17, or the 18.130 print in the TradingKey headline?
  • What do the UBS buy initiation and Zacks Hold upgrade rest on, and what are their price targets?

ADRX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for ADARx Pharmaceuticals Inc. (ADRX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ADRX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ADRX Bull vs. Bear Conversation Board — What's Your Call at $17.00?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ADRX 🐻 50% BEARISH CONVICTION
1. Pick Your Side on ADRX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $18.36 (+8.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is ADRX (D • RQD 51/100) a Buy at $17.00?

Welcome to the ADRX (ADARx Pharmaceuticals Inc.) Roar Pit. Current RQD Composite is 51/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

BE BearTrap_Alert Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $14.28 (-16.0%)
Spot @ $17.00

Pump the brakes on ADRX — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on ADRX, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless ADARx Pharmaceuticals Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

QU QuantViper Verified K Arena Trader 🐂 BULLISH 🎯 Target: $21.08 (+24.0%)
Spot @ $17.00

ADRX cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on ADRX, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $17.00 (52-wk range $16.30 - $23.21), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%